Motif Bio (MTFB) has raised $25.8m (£20m) through the placing of 6.6m shares at 30p with new and existing shareholders. The funds allow for the completion of REVIVE-2 and subsequent regulatory applications. With our strong belief that REVIVE-2 data readout will be positive (finnCap est. 85%), we expect iclaprim to potentially begin commercial sales in early 2019 for the treatment of acute bacterial skin & skin structure infections (ABSSSI). Given the similarities between both REVIVE
07 Jun 2017
Remain positive on REVIVE-2 readout
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Remain positive on REVIVE-2 readout
- Published:
07 Jun 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
10
Motif Bio (MTFB) has raised $25.8m (£20m) through the placing of 6.6m shares at 30p with new and existing shareholders. The funds allow for the completion of REVIVE-2 and subsequent regulatory applications. With our strong belief that REVIVE-2 data readout will be positive (finnCap est. 85%), we expect iclaprim to potentially begin commercial sales in early 2019 for the treatment of acute bacterial skin & skin structure infections (ABSSSI). Given the similarities between both REVIVE